Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18236729 | 0.94 | CYP1A2 (0.55) | ALDH1A1CYP1A2RAD52SLC2A1ADRA2A | |
| SCHEMBL10241565 | 0.89 | ALDH1A1 (0.46) | ALDH1A1CYP1A2RAD52SLC2A1 | |
| SCHEMBL23844656 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP1A2 | |
| SCHEMBL31530916 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP1A2 | |
| SCHEMBL14354979 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CYP1A2RAD52SLC2A1ADRA2A | |
| SCHEMBL13202528 | 0.80 | ALDH1A1 (0.56) | ALDH1A1CYP1A2RAD52SLC2A1 | |
| SCHEMBL21430668 | 0.80 | ALDH1A1 (0.56) | ALDH1A1CYP1A2RAD52SLC2A1ADRA2A | |
| SCHEMBL10229134 | 0.80 | CYP1A2 (0.41) | ALDH1A1CYP1A2 | |
| SCHEMBL13202524 | 0.80 | ALDH1A1 (0.56) | ALDH1A1CYP1A2RAD52SLC2A1 | |
| SCHEMBL18539297 | 0.80 | ALDH1A1 (0.56) | ALDH1A1CYP1A2RAD52SLC2A1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021219091-A2 | QUINOXALINONE DERIVATIVE AS IRREVERSIBLE INHIBITOR OF KRAS G12C MUTANT PROTEIN | 北京泰德制药股份有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2009-06-25 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7288571-B2 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2007-10-30 | — | — | US | disclosed |
| US-5002943-A | Antispasmodic Agents, Bradycardia Treatment | MIHM GERHARD (DE) | 1991-03-26 | — | — | US | disclosed |
| EP-0346745-A1 | Condensed diazepinones, processes for their preparation and pharmaceutical preparations containing them | Dr. Karl Thomae GmbH (DE) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | ALDH1A1 2896/4885CYP1A2 4845/4885RAD52 4026/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ALDH1A1 2896/4885CYP1A2 4845/4885RAD52 4026/4885 |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | ALDH1A1 2373/4885CYP1A2 1290/4885RAD52 1643/4885 |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | ALDH1A1 2373/4885CYP1A2 1290/4885RAD52 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.